-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA BIOTECHNOLOGY DOSES FIRST U.S. PATIENT IN ONGOING PHASE 2 NON-SMALL CELL LUNG CANCER CLINICAL TRIAL

Reuters·09/16/2026 12:15:00

Please log in to view news